Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Jorma Paavonen, Paulo Naud, Jorge Salmerón et al. · The Lancet · 2009 · 1.6K citations

As04-adjuvanted Vaccine, Gynecology, Oncogenic Hpv Types +16

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2004 · 1.6K citations

Vaccination, Vaccine Safety, Vaccine Development +6

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2006 · 1.6K citations · Full text

Vaccination, Vaccinology, Vaccine Development +8

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta et al. · The Lancet Oncology · 2005 · 1.6K citations

Vaccination, Vaccinology, Vaccine Development +9

Against which human papillomavirus types shall we vaccinate and screen? the international perspective

Núbia Muñóz, F. Xavier Bosch, Xavier Castellsagué et al. · International Journal of Cancer · 2004 · 1.1K citations · Full text